Literature DB >> 33057816

Association of elevated neonatal thyroid-stimulating hormone levels with school performance and stimulant prescription for attention deficit hyperactivity disorder in childhood.

Samantha J Lain1, Veronica Wiley2,3, Michelle Jack4,5, Andrew J Martin6, Bridget Wilcken2,3, Natasha Nassar7.   

Abstract

Untreated severe newborn thyroid deficiency causes neurocognitive impairment; however, the impact of mild thyroid deficiency is not known. This study aimed to examine whether mildly elevated neonatal thyroid-stimulating hormone (TSH) levels are associated with poor school performance or stimulant prescription for attention deficit hyperactivity disorder (ADHD). This record-linkage study included 232,790 term-born infants in Australia with a TSH level below newborn screening threshold (< 15 mIU/L). Among our cohort, as TSH levels increased, the proportion of infants born low birthweight via caesarean section and with disadvantaged socioeconomic status increased. Multivariable logistic regression analysis showed that, compared with infants with 'normal' neonatal TSH level (< 5 mIU/L), those with neonatal TSH 10-15 mIU/L had an increased risk of being exempt from school testing (aOR 1.63 (95% CI 1.06-2.69)) or prescribed a stimulant for ADHD (aOR 1.57 (95% CI 1.10-2.24)), adjusted for perinatal and sociodemographic factors. Among a nested analysis of 460 sibling pairs, siblings with 'mildly elevated' TSH levels were more likely to be exempt from school tests compared with siblings with normal TSH levels (aOR 2.53, 95% CI 1.01-6.33).
Conclusion: In this population cohort and sibling analysis, mildly elevated neonatal TSH levels were associated with being exempt from school testing due to significant or complex disability. What is Known: • Newborn screening for severe thyroid hormone deficiency has virtually eliminated congenital hypothyroidism-associated intellectual disability in developed countries. • The impact of mild thyroid hormone deficiency in infants is unclear. What is New: • Children with a mildly elevated neonatal TSH level below current newborn screening cut-offs have an increased likelihood of being exempt from school testing due to significant or complex disability compared with siblings and peers. This study includes a population-based and nested sibling analysis.

Entities:  

Keywords:  Congenital hypothyroidism; Newborn screening; TSH; Thyroid hormone

Mesh:

Substances:

Year:  2020        PMID: 33057816     DOI: 10.1007/s00431-020-03828-9

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  4 in total

1.  Psycho-intellectual development of 3 year-old children with early gestational iodine deficiency.

Authors:  Isolina Riaño Galán; Paloma Sánchez Martínez; María Pilar Mosteiro Díaz; M Francisco Rivas Crespo
Journal:  J Pediatr Endocrinol Metab       Date:  2005-12       Impact factor: 1.634

2.  Screening for congenital hypothyroidism: comparison of borderline screening cut-off points and the effect on the number of children treated with levothyroxine.

Authors:  Shirley Langham; Peter Hindmarsh; Steven Krywawych; Catherine Peters
Journal:  Eur Thyroid J       Date:  2013-05-08

3.  A population-based study on the frequency of additional congenital malformations in infants with congenital hypothyroidism: data from the Italian Registry for Congenital Hypothyroidism (1991-1998).

Authors:  A Olivieri; M A Stazi; P Mastroiacovo; C Fazzini; E Medda; A Spagnolo; S De Angelis; M E Grandolfo; D Taruscio; V Cordeddu; M Sorcini
Journal:  J Clin Endocrinol Metab       Date:  2002-02       Impact factor: 5.958

Review 4.  Optimising outcome in congenital hypothyroidism; current opinions on best practice in initial assessment and subsequent management.

Authors:  Malcolm Donaldson; Jeremy Jones
Journal:  J Clin Res Pediatr Endocrinol       Date:  2012-11-15
  4 in total
  1 in total

1.  [Newborn screening for congenital hypothyroidism and congenital adrenal hyperplasia: Benefits and costs of a successful public health program].

Authors:  Guy Van Vliet; Scott D Grosse
Journal:  Med Sci (Paris)       Date:  2021-05-18       Impact factor: 0.716

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.